{"id":"insulin-degludec-liraglutide","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"10–30","effect":"Hypoglycemia"},{"rate":"5–15","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2107869","moleculeType":"Protein"},"_dailymed":{"setId":"21335fe4-d395-4501-ac2a-2f20d7520da9","title":"XULTOPHY 100/3.6 (INSULIN DEGLUDEC AND LIRAGLUTIDE) INJECTION, SOLUTION [NOVO NORDISK]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin degludec is a long-acting basal insulin that provides steady background glucose control over 24+ hours. Liraglutide is a GLP-1 receptor agonist that stimulates insulin secretion in response to meals, slows gastric emptying, and promotes satiety. Together, they address both fasting and postprandial hyperglycemia while supporting weight loss.","oneSentence":"This combination provides basal insulin coverage via degludec while enhancing glucose-dependent insulin secretion and reducing appetite through liraglutide's GLP-1 receptor agonism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:17.509Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04952779","phase":"","title":"Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-06-02","conditions":"Diabetes Mellitus, Type 2","enrollment":750},{"nctId":"NCT04838743","phase":"","title":"GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-23","conditions":"Diabetes Mellitus, Type 2","enrollment":244},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06925334","phase":"PHASE4","title":"A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-05-20","conditions":"Type 2 Diabetic Patients","enrollment":170},{"nctId":"NCT06113341","phase":"","title":"A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2024-11-07","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT06559722","phase":"PHASE3","title":"A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-08","conditions":"Type 2 Diabetes","enrollment":510},{"nctId":"NCT06449703","phase":"PHASE1","title":"A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects","status":"RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-05-06","conditions":"Healthy","enrollment":44},{"nctId":"NCT06408532","phase":"PHASE4","title":"The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-04-30","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT04666987","phase":"","title":"A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-21","conditions":"Diabetes Mellitus, Type 2","enrollment":359},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT03862716","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05767255","phase":"PHASE3","title":"Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue","status":"UNKNOWN","sponsor":"Hospital Universitario San Ignacio","startDate":"2022-12-01","conditions":"Diabetes Mellitus, Type 2 Treated With Insulin","enrollment":66},{"nctId":"NCT04020445","phase":"","title":"Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes","status":"COMPLETED","sponsor":"Bekes County Central Hospital","startDate":"2016-01-01","conditions":"HBA1c, Body Weight, Hypoglycemia","enrollment":150},{"nctId":"NCT03172494","phase":"PHASE3","title":"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":720},{"nctId":"NCT05324462","phase":"","title":"Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 2","enrollment":175},{"nctId":"NCT05479591","phase":"","title":"A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2022-07-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT05545800","phase":"PHASE3","title":"Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":78},{"nctId":"NCT03823339","phase":"","title":"A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-29","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT04190160","phase":"NA","title":"Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)","status":"COMPLETED","sponsor":"Stefano Rizza","startDate":"2018-11-19","conditions":"Type2 Diabetes","enrollment":35},{"nctId":"NCT02911948","phase":"PHASE3","title":"A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-09-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":210},{"nctId":"NCT02607306","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-11-18","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":819},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT02773368","phase":"PHASE3","title":"A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT04034524","phase":"","title":"Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2019-05-01","conditions":"Diabetes Mellitus, Type 2","enrollment":20000},{"nctId":"NCT03175120","phase":"PHASE3","title":"A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":453},{"nctId":"NCT02501161","phase":"PHASE3","title":"A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-01-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1012},{"nctId":"NCT03292185","phase":"PHASE1","title":"A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-09-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT03959865","phase":"","title":"GLP-1 REceptor Agonists and Real World EvIdeNce","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2018-12-19","conditions":"Type 2 Diabetes","enrollment":6000},{"nctId":"NCT01952145","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-20","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":557},{"nctId":"NCT01676116","phase":"PHASE3","title":"The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":438},{"nctId":"NCT01392573","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-11-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":413},{"nctId":"NCT02420262","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-07-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT01336023","phase":"PHASE3","title":"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-05-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1663},{"nctId":"NCT02754817","phase":"","title":"A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-04-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":611},{"nctId":"NCT01618162","phase":"PHASE3","title":"The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":435},{"nctId":"NCT01664247","phase":"PHASE3","title":"The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-10-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":346},{"nctId":"NCT03070704","phase":"","title":"Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2017-08-16","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02298192","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-11-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT01388361","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":413},{"nctId":"NCT00983021","phase":"PHASE1","title":"Safety and Tolerability of NN9068 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT02100475","phase":"PHASE3","title":"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":31},{"nctId":"NCT01319240","phase":"PHASE1","title":"Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-03","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01916174","phase":"PHASE1","title":"A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-08","conditions":"Diabetes, Diabetes Mellitus, Type 2, Healthy","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":9,"reaction":"DIARRHOEA"},{"count":7,"reaction":"ACUTE KIDNEY INJURY"},{"count":7,"reaction":"NAUSEA"},{"count":6,"reaction":"DRUG INEFFECTIVE"},{"count":5,"reaction":"ABDOMINAL DISTENSION"},{"count":5,"reaction":"DYSPNOEA"},{"count":5,"reaction":"GASTROOESOPHAGEAL REFLUX DISEASE"},{"count":5,"reaction":"HYPERTENSION"},{"count":5,"reaction":"HYPOGLYCAEMIA"},{"count":4,"reaction":"ABDOMINAL PAIN"}],"_approvalHistory":[],"publicationCount":99,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ideglira"],"phase":"marketed","status":"active","brandName":"insulin degludec + liraglutide","genericName":"insulin degludec + liraglutide","companyName":"Hospital Universitario San Ignacio","companyId":"hospital-universitario-san-ignacio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination provides basal insulin coverage via degludec while enhancing glucose-dependent insulin secretion and reducing appetite through liraglutide's GLP-1 receptor agonism. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}